SONIRE’s Clinical Trial Protocol for HIFU therapy in Pancreatic Cancer to be Presented at ISTU2023

SONIRE Therapeutics Inc. (Headquarters: Shinjuku-ku, Tokyo; President and CEO: Tohru Satoh; hereinafter referred to as “SONIRE”), announces that a clinical trial protocol for a HIFU therapy system currently underway in Japan for the treatment of patients with unresectable pancreatic cancer will be presented at the annual meeting of the International Society for Therapeutic Ultrasound held in Lyonn (France) from April 17 to 20, 2023.

Dr. Jun Sofuni, Associate Professor, Department of Gastroenterology, Division of Clinical Medicine, Tokyo Medical University and Chief, Department of Clinical Oncology, Tokyo Medical University Hospital, who is the investigator in charge of this clinical trial, will make two presentations at the following times.

April 18, 12:30 – 13:30 (local time) Poster Session

April 19, 13:30 – 13:48 (local time) Liver and Pancreas Session

Conference website: 

An article about our business and cancer treatment using HIFU (High-Intensity Focused Ultrasound) was recently published in the Nikkei Newspaper. The development of our HIFU therapy system has entered a new stage and is attracting a great deal of attention both domestically and internationally.

We will continue to promote our business in order to realize the wish we put in our company name at the time of our foundation: ” Sonics(Ultrasound) Brings New Future to Cancer Patients and Families.”.

As a result of Tohoku-Israel Startup Global Challenge Program, Tohru Satoh, President & CEO of SONIRE Therapeutics Inc., will participate in a panel discussion and startup pitch.

Exhibit at JHVS2021 has been decided. JHVS2021 will be held in PACIFICO Yokohama